We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CAR T-cell

News List

CARsgen Announces CT041 CAR T-cell Product Candidate Granted RMAT Designation by the FDA prnasia
January 11, 2022
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors...
CAR T-Cell Immunotherapy Rids Woman of Tough-to-Treat Lupus drugs
August 06, 2021
In a first, researchers have used genetically tweaked immune system cells to send a woman's severe lupus into remission.
Fate Therapeutics Announces Treatment of First Patient in Landmark Phase 1 Clinical Trial of FT819, the First-ever iPSC-derived CAR T-Cell Therapy firstwordpharma
August 03, 2021
Fate Therapeutics , inc. announced today that the first patient has been treated with FT819, an off-the-shelf chimeric antigen receptor (CAR) T-cell therapy targeting CD19+ malignancies.